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Alpha-1-antitrypsin (AAT) deficiency results from mutations on the Protease Inhibitor (PI) locus
located in chromosome 14 and has been associated with pulmonary early-onset emphysema
and chronic obstructive pulmonary disease (COPD). African populations show a lower preva-
lence of AAT deficiency compared to Europeans.
Two hundred and two (202) unrelated samples from the Cape Verde archipelago (Northwest
Africa) were genotyped for the two most common AAT deficiency alleles, PI*S and PI*Z, using
PCR e Mediated Site-Directed Mutagenesis.
PI*S mutation in Cape Verde (3.2%) presents one of the highest frequencies in sub-Saharans,
similar to South Africa (3.3%) but lower than Angolans (18.8%), Namibians (14.7%), Nigerians
(6.4%) and Botswains (4.5%). The PI*Z mutation shows lower values (0.2%) than other sub-
Saharan populations, namely Somalia (1.15%), Mali (0.98%)or Nigeria (0.36%). However, many
other sub-Saharan populations, like Botswana, Congo, Cameroon, Angola, Gambia, South Africa,
Mozambique and Namibia, lack the PI*Z mutation.
The frequency of all the AAT deficiency genotypes in the Cape Verde archipelago (PI*ZZ, PI*SS,
and PI*SZ) was estimated to be one of the highest in sub-Saharans (15 per 1000), only lower than
Angola (54 per 1000) and Namibia (22 per 1000).
The results obtained show a high prevalence of the AAT deficiency in Cape Verdeans when
compared to other sub-Saharans a condition that can be explained by a heavy European genetic
influence, characteristic of that population.
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The AAT glycoprotein is a protease inhibitor that protects
lungs against an excessive action of the neutrophil elastase
enzyme.1 AAT deficiency is associated with a progressive,
severe, and life-threatening pulmonary early-onset emphy-
sema and chronic obstructive pulmonary disease (COPD).2
Alpha-1-antitrypsin (AAT) deficiency results from mutations
on the Protease Inhibitor (PI) locus, located in the long armof
chromosome 14.3e6 If AAT deficiency is diagnosed early in
asymptomatic patients, it is possible to modify lifestyle
choices in order to reduce the risk of COPD.7,8
The two most frequent mutations in PI locus are PI*S and
PI*Z, which are responsible for clinically relevant alpha-1-
antitrypsin deficiency.9 These two mutations have different
geographic distributions with PI*S reaching the highest
frequencies in the Iberia Peninsula and PI*Z in Northern
Europe.10
PI*ZZ, PI*SZ and PI*SS are considered to be deficiency
genotypes and both PI*MS and PI*MZ carriers of the
anomaly. PI*ZZ individuals are at higher risk for COPD than
PI*SZ subjects, although for smokers both genotypes indi-
cate a high risk for the disease.11
AAT deficiency, despite being more prevalent in Euro-
peans, has been reported worldwide including sub-Saharan
Africans.12 The high values of PI*Z mutations found in Euro-
pean populations, namely in Latvia (4.51%), Madeira Island
(Portugal, 2.5%), Estonia (2.45%) and Denmark (2.7%),
contrast with Sub-Saharan populations characterized by
a low prevalence of mutations (Somalia: 1.15%; Mali: 0.98%;
Nigeria: 0.36%) or absence (Botswana, Congo, Cameroon,
Angola, Gambia, South Africa, Mozambique and
Namibia).10,12,13 However, the PI*S mutation in several Sub-
Saharans (Angola: 18.8%; Namibia: 14.7%; Nigeria: 6.4%;
Botswana: 4.6%; South Africa: 3.3%; Somalia: 1.7%) reach
frequencies comparable to Europeans (Madeira Island e
Portugal: 18%; Portugal: 13%, Spain: 10.4%; France: 7.6%;
Belgium: 5.4%; Switzerland: 3.8%; Italy: 3%; Netherlands:
3.2%; Latvia 3.1%; Norway: 2.5%).10,12,13
The Cape Verde Archipelago (Northwest Africa) consists
of ten islands located approximately 400 miles west from
Senegal and was inhabited around 1460.The islands were
settled by Europeans (mainly Portuguese) and Sub-Saharan
slaves originating from the West coast of Africa.14,15 Slaves
have always been the vast majority of the population
(around 90%) but studies on mtDNA, STR, Y-chromosome
SNPs and HLA showed that an important European genetic
influence is still perceivable in the extant population.16e20
The present study aims to assess for the first time
unbiased frequencies of PI*S and PI*Z alleles on the Cape
Verde population. The prevalence of the different AAT
deficiency genotypes are also estimated in order to clarify
the genetic susceptibility to COPD in a population with
a high degree of genetic admixture between Europeans and
Sub-Saharans.
Materials and methods
The samples consisted of 202 unrelated young males from
Cape Verde and were collected with informed consent
following the recommendations of the American ThoracicSociety and the European Respiratory Society,21 Genomic
DNA was isolated from whole blood and PI*S and PI*Z
mutations were genotyped using PCR-MSDM (Polymerase
Chain Reaction e Mediated Site-Directed Mutagenesis) as
previously described.22 Allele and genotype frequencies
were determined by gene counting and confidence intervals
assessed with the Exploratory Software for Confidence
Intervals (ESCI JSMS, La Probe University, Melbourne,
Australia) available online.23 The expected numbers of AAT
genotypes were extrapolated based on observed genotype
frequencies, except for Pi*SZ and Pi*ZZ which were calcu-
lated from the HardyeWeinberg equilibrium formula.
Arlequin version 3.11 software was employed to perform an
analysis of molecular variance (AMOVA) based on Euclidean
distances, using Cape Verde and other worldwide pop-
ulations available from the literature.10,12,24,25
Results
In 202 individuals, 7 heterozygote MS (95% CI: 2e12), 3
homozygote SS (95% CI: 0e6), 1 heterozygote MZ (95% CI:
0e3), and no SZ or ZZ were found. Therefore, the
frequency of PI*M (non-S, non-Z) allele was 94.6 (95% CI:
924e968), PI*S allele was 0.32 (95% CI: 15e49); and PI*Z was
0.02 (95% CI: 0e6.4) (Table 1).
The AAT deficiency prevalence in the Cape Verde
archipelago was 1/249,898 for ZZ, 1/67 for SS and 1/7809
for SZ, and the prevalence of carriers was 1/202 for MZ and
1/29 for MS. Given these results, we expect the occurrence
of only 2 subjects with severe AAT deficiency (ZZ). The
frequency of all the AAT deficiency genotypes in the
archipelago (PI*ZZ, PI*SS, and PI*SZ) was estimated to be
one of the highest in sub-Saharans (1.5 per 100), only lower
than Angola (5.4) and Namibia (2.2).12 Details on the
expected numbers of ATT genotypes, and respective
confidence intervals, are shown in Table 1. AAT allele
frequencies in Cape Verde weren’t statistically different
from Botswana (P Z 0.12) and South Africa (P Z 0.15).
Discussion
AsAATdeficiency is underdiagnosedall over theworld, S andZ
frequencydetermination is crucial toestimate theprevalence
of subjects at risk of developing COPD. Knowing the real
extend of deficiency alleles in the population allows the
implementation of early diagnosis mechanisms which can be
applied to asymptomatic patients.
The present study describes for the first time the prev-
alence of AAT PI*S and PI*Z mutations in the Cape Verde
archipelago population revealing one of the highest
frequencies of AAT deficiency genotypes (ZZ, SS and SZ) in
sub-Saharans.
PI*S mutation in Cape Verde (3.2%; 95% CI: 1.5%e4.9%)
shows one of the highest frequencies in sub-Saharans,
similar to South Africans (3.3%) but lower than Angolans
(18.8%), Namibians (14.7%) Nigerians (6.4%) and Boatswains
(4.5%).12 On the other hand, the frequency of the PI*Z
mutation (0.2%; 95% CI: 0%e0.64%) is lower than that found
in other sub-Saharan populations, namely Somalia (1.15%),
Mali (0.98%) and Nigeria (0.36%). However, many other
sub-Saharans, like Botswana, Congo, Cameroon, Angola,
Table 1 Observed allele frequencies and expected numbers of AAT genotypes in Cape Verde archipelago and respective
confidence interval (CI).
Genotype Observed number
(n Z 202)
Cape Verde (n Z 499,796)a Prevalence
(1/x)
95% CI
Number 95% CI
MM (non-S; non-Z) 191 472,807 457,313e488,301 1.06 1.02e1.1
MS 7 17,493 4848e29,988 29 17e103
MZ 1 2474 0ce7312 202 68eþNd
SS 3 7447 0ce15,993 67 31eþNd
SZ 0 64b 0ce850 7809 588eþNd
ZZ 0 2b 0ce140 249,898 3570eþNd
Allele Frequency per 1000 CI 95%
PI*M (non-S; non-Z) 946 924e968
PI*S 32 15e49
PI*Z 2 0e6.4
a Data from Cape Verde National Statistics Institute, 2000.
b Value calculated from HardyeWeinberg Equilibrium formula (p2 þ 2pq þ q2 Z 1).
c We assume zero as lower limit of CI 95% when the result was a negative value.
d We assume plus infinite since lower limit is zero.
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apparently the PI*Z mutation.12
The results obtained in this study not only reflect the
sub-Saharan origin of the Cape Verde population but also
shows the influence of Europeans in the peopling of the
islands. This is in agreement with previous studies using
other markers.16e20 In fact, the relative high prevalence of
both mutations, S and Z, in comparison to other sub-
Saharan populations, is probably a consequence of the
genetic influence of Europeans, especially Portuguese,
where these mutations have a much higher prevalence.12,13
At a sub-Saharan level, Nigerians are the only population
that show frequencies higher than Cape Verde in both
added mutations.12
The high prevalence of AAT deficiency in Cape Verde,
comparing to other sub-Saharans, should drive national
authorities to give special attention to these genetic
mutations as a cause for susceptibility to COPD.
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